Literature DB >> 28379318

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

P F Ferrucci, P A Ascierto, J Pigozzo, M Del Vecchio, M Maio, G C Antonini Cappellini, M Guidoboni, P Queirolo, P Savoia, M Mandalà, E Simeone, S Valpione, M Altomonte, F Spagnolo, E Cocorocchio, S Gandini, D Giannarelli, C Martinoli.   

Abstract

Entities:  

Year:  2018        PMID： 28379318     DOI： 10.1093/annonc/mdx059

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  17 in total

1.  Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.

Authors:  A Passaro; P Mancuso; S Gandini; G Spitaleri; V Labanca; E Guerini-Rocco; M Barberis; C Catania; E Del Signore; F de Marinis; F Bertolini
Journal:  Clin Transl Oncol       Date:  2019-06-28       Impact factor: 3.405

2.  Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.

Authors:  Lihong Peng; Yong Wang; Fen Liu; Xiaotong Qiu; Xinwei Zhang; Chen Fang; Xiaoyin Qian; Yong Li
Journal:  Cancer Immunol Immunother       Date:  2020-04-29       Impact factor: 6.968

3.  Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.

Authors:  Aixa E Soyano; Bhagirathbhai Dholaria; Julian A Marin-Acevedo; Nancy Diehl; David Hodge; Yan Luo; Rami Manochakian; Saranya Chumsri; Alex Adjei; Keith L Knutson; Yanyan Lou
Journal:  J Immunother Cancer       Date:  2018-11-23       Impact factor: 13.751

4.  Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.

Authors:  Paolo A Ascierto; Mariaelena Capone; Antonio M Grimaldi; Domenico Mallardo; Ester Simeone; Gabriele Madonna; Heinrich Roder; Krista Meyer; Senait Asmellash; Carlos Oliveira; Joanna Roder; Julia Grigorieva
Journal:  J Immunother Cancer       Date:  2019-03-29       Impact factor: 13.751

5.  The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.

Authors:  M G Dal Bello; R A Filiberti; A Alama; A M Orengo; M Mussap; S Coco; I Vanni; S Boccardo; E Rijavec; C Genova; F Biello; G Barletta; G Rossi; M Tagliamento; C Maggioni; F Grossi
Journal:  J Transl Med       Date:  2019-03-08       Impact factor: 5.531

6.  Prognostic Value of Combined Analysis of CTLA-4 and PLR in Esophageal Squamous Cell Carcinoma (ESCC) Patients.

Authors:  Cui-Ying Zhang; Juan Zhang; Yun-Fan Ma; Hong Zhe; Ren Zhao; Yan-Yang Wang
Journal:  Dis Markers       Date:  2019-08-14       Impact factor: 3.434

7.  The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma.

Authors:  Michele Guida; Nicola Bartolomeo; Ivana De Risi; Livia Fucci; Andrea Armenio; Ruggero Filannino; Eustachio Ruggieri; Francesco Macina; Michele Traversa; Annalisa Nardone; Francesco Figliuolo; Federica De Luca; Fabio Mele; Stefania Tommasi; Sabino Strippoli
Journal:  Cancers (Basel)       Date:  2019-10-14       Impact factor: 6.639

8.  High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.

Authors:  Issei Sumiyoshi; Takahiro Okabe; Shinsaku Togo; Haruhi Takagi; Hiroaki Motomura; Yusuke Ochi; Naoko Shimada; Mizuki Haraguchi; Rina Shibayama; Yuichi Fujimoto; Junko Watanabe; Moe Iwai; Kotaro Kadoya; Shin-Ichiro Iwakami; Kazuhisa Takahashi
Journal:  J Transl Med       Date:  2021-02-28       Impact factor: 5.531

9.  Preoperative Immune Prognostic Index Can Predict the Clinical Outcomes of Patients with Gallbladder Cancer: Single-Center Experience.

Authors:  Lejia Sun; Dongyue Wang; Mengyuan Zhang; Yukai Jin; Bao Jin; Haifeng Xu; Shunda Du; Yiyao Xu; Haitao Zhao; Xin Lu; Xinting Sang; Shouxian Zhong; Huayu Yang; Yilei Mao
Journal:  Cancer Manag Res       Date:  2020-11-25       Impact factor: 3.989

Review 10.  Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.

Authors:  Elisa Peranzoni; Vincenzo Ingangi; Elena Masetto; Laura Pinton; Ilaria Marigo
Journal:  Front Immunol       Date:  2020-07-24       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.